<DOC>
	<DOCNO>NCT02630628</DOCNO>
	<brief_summary>Prospective , randomize , parallel-group control , open-label , international ( Asian ) multicenter , comparison corticosteroid combine TAC corticosteroid combine MMF .</brief_summary>
	<brief_title>Efficacy Safety Tacrolimus Versus Mycophenolate Lupus Nephritis</brief_title>
	<detailed_description>There accumulate evidence tacrolimus ( TAC ) could serve effective medication treatment lupus nephritis ( LN ) . TAC calcineurin inhibitor , key component first-line combination immunosuppressive regimen kidney transplantation , base proven efficacy prevention treatment allograft rejection acceptable tolerability profile . Although primarily target T lymphocyte activation , immunosuppressive action encompass multiple immune response pathway due complex interaction different cellular soluble immune mediator . Moreover , effect calcineurin inhibitor podocyte morphology function , independent immunosuppressive effect , translate therapeutic efficacy treatment proteinuric glomerular disease membranous nephropathy focal segmental glomerulosclerosis . Recent data short-term study show combination immunosuppressive regimen include TAC corticosteroid without mycophenolate mofetil ( MMF ) appear least effective standard-of-care treatment Class III/IV±V LN , inclusion TAC might lead effective suppression proteinuria . There also preliminary data favorable tolerability use long-term maintenance treatment . This study aim examine role TAC combine corticosteroid , comparison commonly use standard-of-care treatment MMF plus corticosteroid , management lupus nephritis .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Biopsyproven LN Class III/IV±V ( ISN/RPS 2003 ) , biopsy perform within 12 week randomization . 2 . Positive antidsDNA . 3 . Active LN proteinuria ( urine protein/creatinine ratio &gt; 1.0 24hr urine protein &gt; 1.0 g baseline ) , without hematuria . 4 . Both 'incident ' ( i.e . new ) patient 'flare ' patient include . 1 . Renal disease unrelated SLE ( e.g . diabetes mellitus , glomerular tubulointerstitial disease , renovascular disease ) , transplant kidney . 2 . Estimated glomerular filtration rate ( eGFR MDRD ) ≤20 mL/min per 1.73 m2 serum creatinine &gt; 300 micromol/L ( 3.39 mg/dL ) screening . 3 . Renal biopsy show cellular fibrocellular crescent 25 % glomerulus . 4 . CNS severe organ manifestation lupus necessitate aggressive immunosuppressive therapy . 5 . Comorbidities require corticosteroid therapy ( e.g . asthma , inflammatory bowel disease ) . 6 . Treatment prednisolone ( prednisone , equivalent ) &gt; 20 mg/D 4 week within past 3 month . 7 . Treatment MMF &gt; 1.5 g/D 4 week within past 3 month . 8 . Known hypersensitivity intolerability prednisolone ( prednisone , equivalent ) , TAC , MMF dose 1.25 g per day . 9 . Subjects already treatment TAC , cyclosporine calcineurin inhibitor 4 week within past 12 month . 10 . Treatment cyclophosphamide , leflunomide , methotrexate 2 week , use biological agent ( ) regardless duration , within past 6 month ( Note : prior use azathioprine , mizoribine , intravenous immunoglobulin antimalarial allow ) . 11 . Uncontrolled hypertension systolic BP &gt; 160 mmHg diastolic BP &gt; 95 mmHg . 12 . Women pregnant breastfeeding . 13 . Women childbearing potential male partner , refuse use effective birth control method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>tacrolimus</keyword>
</DOC>